Dental Research

U.S. FDA grants approval for oral gingivitis rinse as medical device

Published in Immunotherapy Weekly, May 18th, 2005

Sinclair Pharma plc (SPH.L), a company focused on the acquisition and development of niche patented pharmaceutical products, announced that Decapinol, its oral rinse for the treatment of gingivitis (gum inflammation), has received registration approval from the U.S. Food and Drug Administration (FDA) as a prescription medical device.

Records indicate that Decapinol is the first new chemical entity approved to help prevent and treat gingivitis in the past 30 years.

Gingivitis is an inflammation of the gums caused by bacteria. This condition can lead to periodontitis, which is the main cause of tooth loss. Current treatment of gingivitis includes...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2005-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry